Analyst firm Zacks Investment Research has upgraded Omnicell (OMCL) to a Rank #2 (Buy), reflecting growing confidence in the company’s earnings trajectory. The upgrade follows three consecutive quarters of year-over-year revenue growth, with Omnicell reporting a 12% increase in total revenue for the third quarter of fiscal 2025. Zacks highlighted robust demand for the company’s automated dispensing systems and AI-driven analytics platform, noting that order volumes rose by 15% in its core North American markets over the past six months. This rating change underscores expectations for continued margin expansion driven by higher software subscription renewals and an uptick in service contract revenue, which accounted for approximately 28% of total sales in the latest quarter.

Omnicell will publish its fourth quarter and full year 2025 financial results on Thursday, February 5, 2026, before the U.S. market opens. Management will host a conference call and webcast at 8:30 a.m. ET to discuss detailed performance metrics, including guidance for 2026. Interested analysts and investors can dial (800) 715-9871 within the U.S. or (646) 307-1963 internationally, using Conference ID 4203777. A simultaneous live webcast, along with slides and a replay archive, will be accessible on the Investor Relations section of the company’s website. Last year’s full year results featured non-GAAP operating income growth of 18% and record bookings of $540 million in automated pharmacy solutions.

Since its founding in 1992, Omnicell has carved out a leadership position in intelligent medication management for hospitals, outpatient pharmacies and long-term care facilities. The company combines robotics-based dispensing cabinets, cloud-native analytics tools and AI-enabled inventory optimization to reduce medication errors and lower operational costs. In 2025, Omnicell expanded its service footprint by adding 75 new hospital clients across Europe and Asia Pacific, bringing its global installed base to over 4,200 sites. Management has guided for service revenue growth of 20% in 2026, driven by the rollout of a next-generation AI module designed to predict critical drug shortages and automate reordering workflows.